ClearPoint Neuro's stock has performed well over the past 4 months, supported by solid business fundamentals. Despite the move higher, ClearPoint's valuation is still modest, given the company's ...

(RTTNews) - ClearPoint Neuro, Inc. (CLPT) announced it has received 510(k) clearance for SmartFrame OR Stereotactic System. Enhanced with the latest OR imaging technology, SmartFrame OR offers ...

SOLANA BEACH, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today ...

The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ...

ClearPoint Neuro reported total operating expenses of $11.3 million in the quarter. The company ended the period with $12.4 million in cash and cash equivalents. “Our 2025 fiscal year is off to a ...

ClearPoint Neuro, Inc. (NASDAQ: CLPT) on Friday said it received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2. The ClearPoint Navigation Software Version 3.0.2 has been ...

SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago. These ...

ClearPoint Neuro ( (CLPT)) just unveiled an announcement. On November 6, 2025, ClearPoint Neuro reported its third-quarter financial results, highlighting a 9% year-over-year revenue increase to $8.9 ...

ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech ...

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.18 per share a year ago. These ...